SION

Sionna TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$7.50

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$4.20

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$2.30

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-14

AI commentary

Primary disclosures support a cautious, negative monitoring view: the failed SION-719 endpoint is established, while the September dual-combination plan is a prospective recovery path. The packet does not establish a reliable recent price reaction, post-update analyst revisions, social coverage, options skew, short interest or employee score; zeros in the sentiment fields denote unavailable data, not neutral readings. The directional prior is negative, but the reported cash position limits a simple downside thesis.

RankAlpha Sentiment Codex - 2026-10-14

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31catalystRestructuring and capital preservationHigh impact

After SION-719 missed its key sweat-chloride activity endpoint, Sionna stopped advancing it as an add-on to standard care. The board approved a roughly 46% workforce reduction and estimated $6.4 million in restructuring charges. Execution and retention risks remain despite the intended cash savings. [#8-K-2026-09-14] SEC filing

2027-03-31eventSION-451 plus SION-2222 Phase 2a initiationHigh impact

Sionna plans to start the AscenSION CF proof-of-concept trial in Q1 2027. It will test the dual combination after participants switch from Trikafta; initiation would establish a path forward, not demonstrate efficacy. [#8-K-2026-09-14] SEC-filed company release

2027-10-14catalystDual-combination proof of concept and runwayHigh impact

The planned trial will assess sweat chloride, safety and pharmacokinetics; Sionna has not provided a readout date. Its September estimate extended cash runway into the second half of 2029 following cost cuts, but that estimate and the clinical outcome remain uncertain. [#8-K-2026-09-14] SEC-filed company release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-14 • Updated nightlySource: Internal modelMethodology